Neuronautics, Inc.

Evanston, IL 60201

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $2.54MM
First Award Date 09/30/01
Most Recent Award Date 09/01/07

Key Personnel

Last Name Name Awards Contact
Abraha Aida Abraha 2
Das Arpita Das 2
Khatami Sam Khatami 1

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/07 - 08/31/08

DESCRIPTION (provided by applicant): As a progressive neurodegenerative disorder characterized by accelerated neuronal cell death leading to dementia, Alzheimer's disease (AD) is one of the Nation's greatest medical, social and economic challenges. However, despite the urgency and abundance of research in the field there is still no cure for AD....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/06 - 08/31/07

DESCRIPTION (provided by applicant): As a progressive neurodegenerative disorder characterized by accelerated neuronal cell death leading to dementia, Alzheimer's disease (AD) is one of the Nation's greatest medical, social and economic challenges. However, despite the urgency and abundance of research in the field there is still no cure for AD....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/04 - 07/31/05

DESCRIPTION (provided by applicant): NNI seeks to ameliorate neurodegeneration seen in Alzheimer's disease and other dementias. Toward this end, NNI scientists have targeted neurofibrillary tangle (NFT) formation for drug discovery. These lesions appear in concert with the onset of memory loss in AD, and are in fact the best markers for AD neuro...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/03 - 07/31/04

DESCRIPTION (provided by applicant): NNI seeks to ameliorate neurodegeneration seen in Alzheimer's disease and other dementias. Toward this end, NNI scientists have targeted neurofibrillary tangle (NFT) formation for drug discovery. These lesions appear in concert with the onset of memory loss in AD, and are in fact the best markers for AD neuro...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 02/28/02

DESCRIPTION (provided by applicant): Our goal is to develop novel small molecule antagonists of tau filament formation. Such molecules are expected to be useful therapeutic agents capable of halting the formation of a hallmark pathology common to Alzheimer's disease and other dementias. There are three specifi...